Multi Vitamin Infusion

Hospira Worldwide, Inc.
Hospira, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use M.V.I.-12™ Pharmacy Bulk Package (Multi-Vitamin Infusion without Vitamin K) safely and effectively. See full prescribing information for M.V.I.-12™ Pharmacy Bulk Package (Multi-Vitamin Infusion without Vitamin K). M.V.I.-12™ Pharmacy Bulk Package (Multi-Vitamin Infusion without Vitamin K) dilution for intravenous infusion only. Initial U.S. Approval: 1953RECENT MAJOR CHANGESDosage and Administration (2.1) (2.3) (2.4)                                            06/2012Warnings and Precautions (5.1) (5.2) (5.3) (5.4) (5.5) (5.6) (5.7) (5.8)  06/2012INDICATIONS AND USAGEM.V.I.-12™ Pharmacy Bulk Package is indicated for prevention of vitamin deficiency in adults and children aged 11 years and above who are on warfarin anticoagulant therapy receiving home parenteral nutrition. (1)DOSAGE AND ADMINISTRATION M.V.I.-12™ is ready for immediate use in adults and children aged 11 years and above when added to intravenous infusion fluids. (2) M.V.I.-12™ SHOULD BE ASEPTICALLY TRANSFERRED TO THE INFUSION FLUID. (2.3) DOSAGE FORMS AND STRENGTHSM.V.I.-12™ Pharmacy Bulk Package is a sterile product consisting of two vials labeled Vial 1 (50 mL) and Vial 2 (50 mL). The mixed solution (100 mL) will provide ten 10 mL single doses. (3)CONTRAINDICATIONSHypersensitivity to any of the vitamins in this product or an existing hypervitaminosis. (4)WARNINGS AND PRECAUTIONS This product contains aluminum that may be toxic. (5.1) Studies have shown that vitamin A may adhere to plastic, resulting in inadequate vitamin A administration in the doses recommended with M.V.I.-12™. (5.2) M.V.I.-12™ may not correct long standing specific vitamin deficiencies. The administration of additional doses may be required. (5.3) Allergic reactions such as urticaria, periorbital and digital edema, have been reported following intravenous administration of thiamine. (5.4) Hypervitaminosis A has been reported in patients with renal failure receiving 1.5 mg/day retinol and in patients with liver disease. (5.5) Do not administer M.V.I.-12™ to patients with suspected or diagnosed megaloblastic anemia prior to the blood sampling for the detection of the folic acid and cyanocobalamin deficiencies. (5.6) Blood vitamin concentration should be periodically monitored to determine if vitamin deficiencies or excesses are developing. (5.7) Ascorbic acid in the urine may cause negative urine glucose determination. (5.8) Side EffectsThere have been rare reports of the following types of reactions: Allergic — anaphylactoid reactions following large intravenous doses of thiamine, urticaria, periorbital and digital edema (6) Dermatologic — rash, erythema, pruritus (6) CNS — headache, dizziness, agitation, anxiety (6) Ophthalmic — diplopia (6) To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or electronically at ProductComplaintsPP@hospira.com, or FDA at 1-800-FDA-1088 or   www.fda.gov/medwatch . DRUG INTERACTIONSA number of interactions between vitamins and drugs have been reported. The following are examples of these interactions:Physical Incompatibilities: Acetazolamide (2.4) Intravenous chlorothiazide sodium (2.4) Aminophylline (2.4) Ampicillin (2.4) Moderately alkaline solutions (2.4) Tetracycline HCl (2.4) Calcium salts such as calcium gluconate (2.4) Vitamin K bisulfite or sodium bisulfite (2.4) Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid have been reported to decrease the antibiotic activity of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin (7.1) Bleomycin (7.1) Clinical Interactions: Phenytoin (7.1) Levodopa (7.1) Chloramphenicol (7.2) USE IN SPECIFIC POPULATIONS Pregnant and Nursing Mothers: Pregnant women should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonpregnant women. (8.1, 8.3) Pediatric Use: Safety and effectiveness in children below the age of 11 years have not been established. (8.4) Monitor calcium and phosphorus levels in patients with renal impairment. (8.6) Monitor vitamin A level in patients with liver disease, high alcohol consumption. (8.7)

FULL PRESCRIBING INFORMATION: CONTENTS*

• 1 MULTI VITAMIN INFUSION INDICATIONS AND USAGE
• 2 MULTI VITAMIN INFUSION DOSAGE AND ADMINISTRATION
  • 2.1 Starting Dose, Dose Range and Route of Administration
  • 2.2 Monitoring
  • 2.3 Instructions for Intravenous Administration
  • 2.4 Drug Incompatibilities
• 3 DOSAGE FORMS AND STRENGTHS
• 4 MULTI VITAMIN INFUSION CONTRAINDICATIONS
• 5 WARNINGS AND PRECAUTIONS
  • 5.1 Aluminum Toxicity
  • 5.2 Adherence of Vitamin A to Plastic
  • 5.3 Intravenous Fat Emulsions
  • 5.4 Allergic Reactions to Thiamine
  • 5.5 Hypervitaminosis A
  • 5.6 Blood Sampling of Megaloblastic Anemia Patients
  • 5.7 Monitor Blood Vitamin Concentrations
  • 5.8 Interference with Urine Glucose Testing
• 6 MULTI VITAMIN INFUSION ADVERSE REACTIONS
• 7 DRUG INTERACTIONS
  • 7.1 Clinical Interactions Affecting Drug Levels
  • 7.2 Clinical Interactions Affecting Vitamin Levels
• 8 USE IN SPECIFIC POPULATIONS
  • 8.1 Pregnancy
  • 8.3 Nursing Mothers
  • 8.4 Pediatric Use
  • 8.6 Patients with Renal Impairment
  • 8.7 Patients with Liver Impairment
• 10 OVERDOSAGE
• 11 MULTI VITAMIN INFUSION DESCRIPTION
• 13 NONCLINICAL TOXICOLOGY
  • 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
• 16 HOW SUPPLIED/STORAGE AND HANDLING
• 17 PATIENT COUNSELING INFORMATION

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

M.V.I.-12 ™ Pharmacy Bulk Package (Multi-Vitamin Infusion without vitamin K) is indicated for the prevention of vitamin deficiency in adults and children aged 11 years and above on warfarin anticoagulant therapy receiving parenteral nutrition.

The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy.

2 DOSAGE AND ADMINISTRATION

• M.V.I.-12™ is ready for immediate intravenous use in adults and children aged 11 years and above when added to intravenous infusion fluids. Do not administer M.V.I.-12™ as a direct, undiluted intravenous injection as it may cause dizziness, faintness, and tissue irritation.

2.1 Starting Dose, Dose Range and Route of Administration

The starting dose is one 10 mL daily dose added directly to an intravenous fluid. Patients with multiple vitamin deficiencies or with increased vitamin requirements may need multiple daily dosages as indicated. Some patients do not maintain adequate levels of certain vitamins when this formulation in recommended amounts is the only source of vitamins. 

2.2 Monitoring

Blood vitamin concentrations should be monitored to ensure maintenance of adequate levels, particularly in patients receiving parenteral multivitamins as the only source of vitamins for long periods of time.

2.3 Instructions for Intravenous Administration

The solution must be prepared prior to intravenous administration.

•    Aseptically transfer the contents of the 50 mL Vial 1 into 50 mL Vial 2. The mixed solution will provide ten 10 mL single doses. Once closure system has been compromised, withdrawal of container contents should be completed within 4 hours. Mixed solution may be stored for up to 4 hours refrigerated. Discard unused portion.

•    Do not administer M.V.I.-12™ as a direct, undiluted intravenous injection as it may cause dizziness, faintness, and tissue irritation.

•    Utilizing a suitable sterile automated compounding device or dispensing pin for accuracy, aseptically transfer each 10 mL dose into a plastic or glass bottle containing at least 500 – 1000 mL intravenous total parenteral nutrition solution containing dextrose or saline. Discard unused portions. This infusion solution may be stored up to 24 hours refrigerated.

•    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

•    Handling of M.V.I.-12™ solution, including preparation of the Pharmacy Bulk Pack, should be restricted to a suitable work area, such as a laminar flow hood. 

2.4 Drug Incompatibilities

•    M.V.I.-12™ (Multi-Vitamin Infusion without vitamin K) is not physically compatible with moderately alkaline solutions such as a sodium bicarbonate solution and other alkaline drugs such as acetazolamide sodium, aminophylline, ampicillin sodium, and chlorothiazide sodium.

•    Folic acid is unstable in the presence of calcium salts such as calcium gluconate.

•    Vitamin A and thiamine in M.V.I.-12™ may react with bisulfite solutions such as sodium bisulfite or vitamin K bisulfate. Patients should be monitored for vitamin A and thiamine deficiencies.

•    Consult appropriate references for listings of physical and chemical compatibility of solutions and drugs with the vitamin infusion. In such circumstances, admixture or Y-site administration with vitamin solutions should be avoided.

3 DOSAGE FORMS AND STRENGTHS

M.V.I.-12™ Pharmacy Bulk Package is a sterile product consisting of two vials labeled Vial 1 (50 mL) and Vial 2 (50 mL). The mixed solution (100 mL) will provide ten 10 mL single doses [ see Description (11) ].

4 CONTRAINDICATIONS

M.V.I.-12™ is contraindicated in patients who have a history of hypersensitivity to any of the vitamins in this product or existing hypervitaminosis due to any vitamins contained in this formulation.

5 WARNINGS AND PRECAUTIONS

5.1 Aluminum Toxicity

M.V.I.-12™ contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 microgram per kg per day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

5.2 Adherence of Vitamin A to Plastic

5.3 Intravenous Fat Emulsions

5.4 Allergic Reactions to Thiamine

5.5 Hypervitaminosis A

5.6 Blood Sampling of Megaloblastic Anemia Patients

5.7 Monitor Blood Vitamin Concentrations

5.8 Interference with Urine Glucose Testing

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other section of the labeling.

• Allergic and anaphylactoid reactions following intravenous administration of thiamine [ see Warnings and Precautions (5.4) ].
• Hypervitaminosis A [ see Warnings and Precautions (5.5) ].

Other adverse reactions:

Dermatologic : rash, erythema, pruritus

CN S: headache, dizziness, agitation, anxiety

Ophthalmic : diplopia

7 DRUG INTERACTIONS

A number of drug interactions between vitamins and other drugs have been reported. Consult appropriate references for additional specific vitamin-drug interactions. The following are examples of these types of interactions:

7.1 Clinical Interactions Affecting Drug Levels

Folic acid

Phenytoin metabolism may be increased by folic acid. Low serum concentration of phenytoin may result in increased seizure frequency.

Patient’s response to methotrexate therapy may be decreased by folic acid.

Pyridoxine

The metabolism of levodopa may be increased and its efficacy may be decreased by pyridoxine.

Antibiotics

Antibiotic activity of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin is decreased by thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid. Bleomycin is inactivated in vitro by ascorbic acid and riboflavin.

7.2 Clinical Interactions Affecting Vitamin Levels

Hydralazine, Isoniazid

Pyridoxine requirements may be increased by concomitant administration of hydralazine or isoniazid.

Chloramphenicol

In patients with pernicious anemia, the hematologic response to vitamin B₁₂ therapy may be inhibited by concomitant administration of chloramphenicol.

Phenytoin

Serum folic acid concentrations may be decreased by phenytoin and, therefore it should be avoided in pregnancy.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

M.V.I.-12™ has not been studied in pregnant women. Pregnant women should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may be different than nonpregnant women.

8.3 Nursing Mothers

M.V.I.-12™ has not been studied in lactating women. Lactating women should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may be different than a nonlactating woman. Caution should be exercised when M.V.I.-12™ Pharmacy Bulk Package is administered to a nursing woman.

8.4 Pediatric Use

Safety and effectiveness of M.V.I.-12™ in children below the age of 11 years have not been established.

8.6 Patients with Renal Impairment

M.V.I.-12™ has not been studied in patients with renal impairment. Monitor renal function, calcium, phosphorus and vitamin A levels in patients with renal impairment [ see Warning and Precautions (5.1, 5.5) ] .

8.7 Patients with Liver Impairment

M.V.I.-12™ has not been studied in patients with liver impairment. Monitor vitamin A level in patients with liver disease, high alcohol consumption [ see Warning and Precautions (5.5) ] .

10 OVERDOSAGE

There is no clinical experience with M.V.I.-12™ overdosage. Signs and symptoms of acute or chronic overdosage may be those of individual M.V.I.-12™ component toxicity.

11 DESCRIPTION

M.V.I.-12™ Pharmacy Bulk Package: A sterile product consisting of two Type 1, amber glass vials labeled Vial 1 (50 mL) and Vial 2 (50 mL). The mixed solution will provide ten single doses of 10 mL each.

“Aqueous” multivitamin formula for intravenous infusion: M.V.I.-12™ (Multi-Vitamin Infusion without vitamin K) makes available a combination of important fat-soluble and water-soluble vitamins in an aqueous solution, formulated specially for incorporation into intravenous infusions. Through special processing techniques, the liposoluble vitamins A, D, and E have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity and fertility studies were not performed.

16 HOW SUPPLIED/STORAGE AND HANDLING

M.V.I.-12 ™ PHARMACY BULK PACKAGE

NDC 61703-423-83    2 Boxes of 10 vials, 50 mL each (5 Vial 1 and 5 Vial 2).

Mix contents of Vial 1 and Vial 2 to provide ten 10 mL single doses.

Minimize the exposure of M.V.I.-12™ to the light, because vitamins A, D and riboflavin are light sensitive.

Store at 2-8°C (36-46°F).

17 PATIENT COUNSELING INFORMATION

• Instruct patient that M.V.I.-12™ is indicated for the prevention of vitamin deficiency in patients on warfarin anticoagulant therapy receiving parenteral nutrition.
• M.V.I.-12™ is contraindicated in patients who have a history of hypersensitivity to any of the vitamins in this product or existing hypervitaminosis due to any vitamins contained in this formulation. Obtain detailed allergy and concomitant drug information from the patient, as well as if they have any kidney or liver impairment, and if they are pregnant, prior to M.V.I.-12™ administration.
• Tell patients to watch for signs of allergic reactions such as urticaria, periorbital and digital edema, which have been reported following intravenous administration of thiamine.
• Instruct patients with renal impairment to immediately report signs of hypervitaminosis A, manifested by nausea, vomiting, headache, dizziness, blurred vision, which has been reported in patients with renal failure receiving 1.5 mg/day retinol and in patients with liver disease.
• Instruct patients to report other adverse reactions such as rash, erythema, pruritus, headache, dizziness, agitation, anxiety, and diplopia.
• Explain the significance of periodic monitoring of blood vitamin concentrations to determine if vitamin deficiencies or excesses are developing and the need to monitor renal function, calcium, phosphorus, aluminum and vitamin A levels in patients with renal impairment.

Revised: 06/2012

                                                                               EN-3073

Manufactured by

Hospira, Inc., Lake Forest, IL 60045 USA

RL-3298

RL-2776